MSC Therapy for Erectile Dysfunction
Patient Progression Report — Clinical outcomes from 90 patients treated with Wharton's Jelly mesenchymal stromal cell therapy for erectile dysfunction.
90
Patients Treated
Single application protocol
Jan 2022 – May 2023
Study Period
17-month follow-up
+25%
IIEF-5 Improvement
3.37 point average increase
85%
Response Rate
At 12-month follow-up
Clinical Care Program Overview
From January 2022 to May 2023, 90 patients were treated at our clinic for Erectile Dysfunction using Wharton's Jelly-derived mesenchymal stromal cells (WJ-MSCs). Each patient received a single intracavernous application as part of our standardized regenerative medicine protocol.
Patients agreed to participate via a secure clinical data platform and share their clinical outcomes for research purposes. All data was collected using internationally validated assessment instruments including the IIEF-5 and SF-12 questionnaires.
Our clinical team continues to monitor patients beyond the 12-month mark, and this report will be updated as additional long-term data becomes available.
Figure 1: Patient Age Distribution
Distribution of 90 patients by age group. The majority of patients fell within the 25–44 age range, with the highest concentration in the 25–29 group.
Figure 2: IIEF-5 Erectile Function Score
The International Index of Erectile Function (IIEF-5) was used to diagnose the presence and severity of erectile dysfunction. Scores range from 5 to 25, with higher scores indicating better function.
Key Finding: +3.37 points (↑25%) average improvement at 12 months post-therapy in patients with a baseline score of ≤ 21.
| Time Point | Respondents | Response Rate | Avg IIEF-5 Score |
|---|---|---|---|
| Pre-therapy | 47 patients | 100% | 13.48 |
| 3 Months | 39 patients | 83% | 15.21 |
| 6 Months | 39 patients | 83% | 16.02 |
| 12 Months | 40 patients | 85% | 16.85 |
Figure 3: SF-12 Health-Related Quality of Life
Quality of life was evaluated using the SF-12 health questionnaire, which measures well-being and functional capacity on a 0–100 scale (higher = better health). Two domains are assessed:
- Physical Domain: Problems with daily activities due to physical health — evaluates physical function, physical role, body pain, and general health.
- Mental Domain: How the patient feels — considers vitality, social function, emotional role, and mental health.
Physical Domain: +5.95 points (↑10%)
Mental Domain: +8.11 points (↑14%)
Methodology & Clinical Notes
Treatment Protocol
Each patient received a single intracavernous injection of Wharton's Jelly-derived mesenchymal stromal cells (WJ-MSCs). Cells were processed and quality-controlled in our GMP-compliant laboratory, ensuring viability above 95% and sterility certification for every batch.
Assessment Instruments
IIEF-5 (International Index of Erectile Function): A 5-item validated questionnaire scoring 5–25, widely used as the gold standard for ED severity assessment. Scores of ≤21 indicate some degree of erectile dysfunction.
SF-12 (Short Form-12 Health Survey): A 12-item questionnaire that produces physical and mental component summary scores (0–100), providing a comprehensive snapshot of health-related quality of life.
Data Collection
All patients consented to participate and share clinical data via a secure web-based clinical data platform. Follow-up assessments were conducted at 3, 6, and 12 months post-treatment. Response rates remained high throughout the study period (83–85%).
Ongoing Monitoring
Our clinical team continues to monitor patients beyond the initial 12-month follow-up period. This report will be updated as additional long-term outcome data becomes available.
Reports from our scientific and medical staff are prepared to provide objective assessments on patient outcomes. Data is analyzed based on scales and research methodologies widely accepted as standard by the global scientific community. Individual results may vary. Read our full medical disclaimer.
Considering MSC Therapy for Erectile Dysfunction?
Schedule a confidential, no-obligation consultation with our specialists to discuss whether regenerative medicine may be right for you.
Or call directly: +90 534 856 92 92